Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CardiolRx (cannabidiol) in recurrent pericarditis
NCT05494788Phase 2Completed
- Sponsor
- Cardiol Therapeutics Inc.
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in recurrent pericarditis, sponsored by Cardiol Therapeutics Inc. Primary endpoint: 11-point Numerical Rating Scale Pain at 8 weeks. Started Jan 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT05494788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494788.